Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
This product is not recommended for children or growing adolescents, or pregnant or lactating women
Clinical trials that led to regulatory approval did not identify back pain as occurring at significantly higher rates in treatment groups compared to placebo
Additional information Active Ingredients Active Ingredients per mL Pack Sizes 50mL multi-dose vial Directions For Use Administer via intramuscular (IM) injection
.webp)
Brinsupri (Brensocatib) Projected peak annual sales: USD 4.3 billion Brensocatib is the worlds first dipeptidyl peptidase-1 (DPP1) inhibitor and the first drug specifically approved for noncystic fibrosis bronchiectasis, a chronic inflammatory lung disease
CAS: 137525-51-0
US$ 23.53
US$ 28.69
:format(webp))
US$ 27.04
